A pharmacy chain has recalled 22 vials of compounded tirzepatide injections after the FDA identified serious flaws in its sterile-drug production process. The recall, announced on October 19, came after a warning letter from the agency citing substantial deficiencies in the facility’s compounding practices. This situation highlights growing concerns about the safety of compounded glucagon-like peptide-1 receptor agonists (GLP-1s), a class of drugs widely used to treat diabetes and obesity.
Compounding pharmacies customize medications for individual patient needs, such as adjusting dosages or removing allergens. Unlike FDA-approved drugs, however, these versions do not undergo the same rigorous premarket review for safety, effectiveness, or quality. When demand for GLP-1s exceeded supply in 2022, federal shortage designations allowed compounders to fill gaps in the market. The FDA declared the tirzepatide shortage resolved in December 2024 and semaglutide shortages resolved in February 2025, ending the legal basis for mass-producing near-identical copies of approved drugs.
Yet compounded GLP-1s remain available, partly because brand-name treatments can cost over $1,000 a month without insurance. Advocates argue that lower prices and individualized formulations preserve access for patients whose needs aren’t met by existing approved products. But affordability alone doesn’t guarantee equivalence to FDA-reviewed medications. A 2026 study identified a previously unreported impurity in sampled compounded tirzepatide-vitamin B12 products, reinforcing concerns about contamination and manufacturing inconsistencies.
Federal laws limit compounding loopholes
Federal law restricts what can be compounded and prohibits routine mass production of essentially identical copies when approved drugs are available, except under narrow conditions. Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act establish two pathways for compounding, but neither authorizes large-scale production of near-duplicates without meeting strict criteria. States cannot override these federal limits, though they may impose additional quality requirements.
Oversight is fragmented, with the FDA regulating registered outsourcing facilities and state pharmacy boards handling many compounding pharmacies. This division has allowed some companies to market combination products—such as tirzepatide with added vitamin B12—as “personalized” alternatives, even when the changes don’t justify a legitimate medical need. The FDA has warned sellers about misleading claims, but enforcement gaps persist.
Researchers at Washington State University’s College of Pharmacy have linked compounded GLP-1 use to adverse events and dosing errors. In a Diabetes Care article, professor Joshua J. Neumiller and colleagues note that compounding expanded during shortages but raises risks from variable concentrations, incorrect salt forms, and manufacturing inconsistencies. They recommend prioritizing FDA-approved medications when available and tightening enforcement of compounding standards.
Experts demand stricter oversight and testing
The regulatory gray zone around compounded GLP-1s has drawn scrutiny from legal and public health experts. In the UMKC Law Review, student Angelina Ferrara argues that current oversight fails to address long-term drug effects, inadequate labeling, and unchecked promotion by telehealth companies and social media influencers. Meanwhile, professors Joseph Mattingly II and Rena M. Conti, writing in JAMA Health Forum, propose stricter advertising standards for compounded drugs and an independent task force to review drug shortage designations.
Industry research further highlights the risks. A team led by Eli Lilly’s Brad Jordan identified a tirzepatide-B12 impurity in compounded products, along with wide variations in potency. The findings suggest systemic issues in quality control and testing for compounded medications. Jordan’s group recommends mandatory pre-market testing for compounded drug vendors before they can market their products.
Apollo Care’s Jared Dudding acknowledges safety concerns but argues that compounded GLP-1s provide affordable alternatives to brand-name drugs like Wegovy and Ozempic. He notes that FDA-registered outsourcing facilities meet stricter manufacturing standards, offering a safer option than unregulated sources. Dudding calls for expanded insurance coverage or payment assistance programs to address cost barriers while maintaining oversight.
FDA flags repeated violations in recalled batches
The FDA’s warning letter to Apothecary Pharma outlined specific deficiencies in its sterile-compounding facility, including failures to prevent microbial contamination and maintain proper documentation of production records. The agency cited repeated violations of current good manufacturing practices (CGMP), which govern how sterile drugs are prepared. These lapses contributed to the recall of the 22 vials, though the FDA did not disclose whether patients had reported adverse reactions linked to the contaminated batches. The letter also noted that Apothecary Pharma had not fully addressed prior warnings issued in 2023, when inspectors found similar issues during a routine review.
State pharmacy boards, which regulate most compounding pharmacies, have taken varied approaches to enforcing federal standards. Others, however, lack the resources to conduct regular inspections. The Diabetes Care study highlighted this inconsistency, noting that adverse-event reports for compounded GLP-1s often go underreported due to limited state-level tracking systems. Researchers found that dosing errors, such as incorrect concentrations or wrong salt forms, were more common in compounded products than in FDA-approved versions, particularly when pharmacies sourced ingredients from unregulated suppliers.
For example, the tirzepatide-vitamin B12 impurity identified by Eli Lilly’s research team was not listed on any compounded product packaging. Without mandatory disclosure requirements, patients may unknowingly receive medications with untested additives or degraded potency. The study’s lead author, Joshua J. Neumiller, called for pharmacies to adopt transparent labeling practices, including batch-specific testing results, to align with FDA-approved drug standards.